Copd
Asthma-related ED visits, hospitalizations linked to increased mortality
SAN FRANCISCO — Mortality rates specific to asthma have been falling, according to an abstract presented at the American Thoracic Society International Conference.
Diagnostic schema identifies individuals with COPD without airflow obstruction
SAN FRANCISCO — Using imaging and respiratory symptoms, researchers identified up to 15.4% of individuals without airflow obstruction as having COPD, according to research presented at the American Thoracic Society International Conference.
FDA approves mepolizumab for COPD with eosinophilic phenotype
The FDA granted approval to mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, according to a GSK press release.
Mepolizumab lowers severe exacerbation risk in COPD, type 2 inflammation at 104 weeks
SAN FRANCISCO — Patients with COPD and type 2 inflammation receiving mepolizumab vs. placebo had decreased moderate and severe exacerbation rates and fewer ED visits per exacerbation at 104 weeks, according to study findings.
Dupilumab helps patients with COPD, type 2 inflammation avoid negative outcomes
SAN FRANCISCO — The likelihood for avoidance of five clinically important outcomes in patients with COPD and type 2 inflammation was greater with dupilumab vs. placebo, according to findings from a win ratio analysis.
Higher self-reported stress linked to poorer respiratory health, quality of life in COPD
Former smokers with COPD reporting higher perceived stress had poorer scores on respiratory health assessments, according to results published in Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation.
Women face elevated risk for COPD regardless of cigarette smoking status
The risk for COPD was heightened among women vs. men who ever smoked, and this was also true among women vs. men who never smoked, according to results published in BMJ Open Respiratory Research.
Mepolizumab reduces exacerbations in COPD with type 2 inflammation
With mepolizumab vs. placebo, patients with COPD and type 2 inflammation experienced significantly fewer moderate/severe exacerbations in a year, according to results published in The New England Journal of Medicine.
Exclusive e-cigarette use raises COPD risk but not type 2 diabetes or heart failure risk
Individuals using e-cigarettes exclusively had a significantly elevated risk for COPD, whereas this was not found when assessing the risk for type 2 diabetes or heart failure, according to data published in Nicotine and Tobacco Research.
FDA-cleared AI-powered lung sound detection tool brings specialist to primary care, home
The FDA has granted clearance to TytoCare’s AI-powered Tyto Insights for Lung Sounds to detect rhonchi, marking the third lung sound alongside wheeze and crackles to receive the designation, according to a press release.